| Eli Lilly: Patient safety is foremost concern | Posted on 29/08/2008 in Pharmacy Supplier News Eli Lilly has restated that patient safety is its foremost concern in the ongoing matter surrounding Byetta (exenatide) injection and the risk of pancreatitis.
Together with Amylin Pharmaceuticals, the company has provided additional context for an alert from the US Food and Drug Administration relating to the compound.
Eli Lilly said its prescribing information for Byetta has included information regarding pancreatitis since 2006.
The company also noted that type 2 diabetes patients have three times the risk of developing pancreatitis than those without the disease, according to one recent study.
Orville G Kolterman, senior vice-president of research and development at Amylin, said: "It is important to understand that pancreatitis, an inflammatory condition of the pancreas, is a rare event."
He added that Byetta has a positive benefit-risk profile for patients with type 2 diabetes.
In June 2008, Eli Lilly reported the results of a year-long study of Byetta in these patients at the annual scientific sessions of the American Diabetes Association in San Francisco.Other news stories from 29/08/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
